Patients who have immune-related adverse events when treated for non–small cell lung cancer (NSCLC) may live longer than those without these complications, according to a new study. In a retrospective cohort study that included more than 800 patients with NSCLC who underwent treatment with immune checkpoint inhibitors...
.png)
Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved
